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Abstract
 .Although human choriogonadotropin hCG plays a crucial role in the regulation of the menstrual cycle and maintenance
of pregnancy, little is known about the other functions. However, recently hCG receptors have been identified in
nongonadal cells. The objective of the current study was to determine the effect of hCG on the production of nitric oxide
 .  .NO . Stimulation of RAW 264.7 cells with hCG after treatment with recombinant interferon-g rIFNg resulted in
increased NO synthesis. hCG had no effect on NO synthesis itself. NO production was inhibited by N G-monomethyl-L-
arginine. rIFNg in combination with hCG showed marked increase of the expression of the inducible nitric oxide synthase
 .iNOS gene. In addition, synergy between rIFNg and hCG was mainly dependent on hCG-induced tumor necrosis factor-a
 .TNF-a secretion. All the preparations of hCG were endotoxin free. These results suggest that the capacity of hCG to
increase NO production from rIFNg-primed RAW 264.7 cells is the result of hCG-induced TNF-a secretion. q 1997
Elsevier Science B.V.
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1. Introduction
 .Human choriogonadotropin hCG is a hormone
that is produced by the trophoblasts of the placenta
and functions in the maintenance of the pregnancy
w x1 . It is a 41 kDa arb heterodimeric glycoprotein of
 .which the a-subunit 15 kDa carries two N-linked
 .carbohydrate chains and the b-subunit 26 kDa has
w xtwo N- and four O-linked chains 1–3 . hCG binds to
Abbreviations: hCG, human choriogonadotropin; NO, nitric
oxide; rIFNg, recombinant interferon-g; iNOS, inducible nitric
oxide; TNF-a , tumor necrosis factor-a; N GMMA, N G-mono-
methyl-L-arginine; LPS, lipopolysaccharide
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a common receptor, of which cDNA is available from
w xseveral mammalian species, i.e., mouse 4 , human
w x w x w x5 , pig 6 , and rat 7 . Previous work has shown that
treatment with hCG can induce effects to cross the
w xspecies barrier 8–10 .
 .Nitric oxide NO is generated from the terminal
guanido nitrogen atom of L-arginine by NO synthase
w x11 . The activity of NO synthase can be inhibited
competitively by substrate analogs such as N G-
 G . w xmonomethyl-L-arginine N MMA 12 . NO has
multiple biological actions, serving as a second mes-
senger or being toxic when it generates reactive
w xoxygen intermediates 13 . NO has also been shown
to regulate ovarian function and may serve as a
w xmediator of the ovulatory process 14 . In the rat
ovarian follicles, treatment with hCG increases follic-
0167-4889r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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ular production of nitrite, a stable metabolite of NO
w x10 .
The present study was designed to test the accumu-
lation of nitrite in supernatants of rIFNg alone and
rIFNg plus hCG stimulated RAW 264.7 cells prepa-
rations. The accumulation of the specific mRNA for
 .inducible nitric oxide synthase iNOS was measured
by Northern blotting. In addition, we report herein
that synergy between rIFNg and hCG is mainly
dependent on hCG-induced TNF-a secretion.
2. Materials and methods
2.1. Materials
 6 y1.Murine rIFNg 1=10 U mg and recombinant
 5 y1.tumor necrosis factor-a rTNF-a: 1=10 U ml
 .were purchased from Genzyme Munchen, Germany .
 .Lipopolysaccharide LPS from E. coli, hCG, L-
 .arginine, LiCl, urea, N- 1-naphthyl -ethylenediamine
dihydrochloride, sodium nitrite, and sulfanilamide
 .were purchased from Sigma St. Louis, MO .
Agarose, phenol, Moloney murine leukemia virus
reverse transcriptase, RNasin, DNA polymerase I,
Taq polymerase, and deoxynucleotide triphosphate
were purchased from Life Technologies Gaithers-
.  .burg, MD . DuPont NEN Boston, MA was the
w 32 x  .source of a- P dCTP. pBluescript II KS y plas-
 .mid was purchased from Stratagene San Diego, CA .
G N MMA was purchased from Calbiochem San
.Diego, CA . All reagents and media for tissue culture
experiments were tested for their LPS content with
use of a colorimetric Limulus amoebocyte lysate
 y1assay detection limit, 10 pg ml ; Whittaker Bio-
.products, Walkersville, MD . None of these reagents
 .including hCG contained endotoxins. Ninety-six-
well tissue culture plates and 100 mm diameter petri
 .dishes were purchased from Nunc Naperville, IL .
 y1.DMEM containing L-arginine 84 mg l , HBSS,
FCS, and other tissue culture reagents were pur-
chased from Life Technologies.
2.2. Cell cultures
RAW 264.7 cells, a macrophage-like cell line,
were obtained from the American Type Culture Col-
lection, Rockville, MD. The cells were grown in
 .RPMI 1640 Life Technologies with 10% FCS and
antibiotics at 378C in 5% CO .2
2.3. Measurement of nitrite concentration
NO synthesis in cell cultures was measured by a
microplate assay method, as previously described
w x15 . To measure nitrite, 100 ml aliquots were re-
moved from conditioned medium and incubated with
an equal volume of Griess reagent 1% sulfanil-
 .amider0.1% N- 1-naphthyl -ethylenediamine dihy-
.drochlorider2.5% H PO at room temperature for3 4
10 min. The absorbance at 540 nm was determined in
a Titertek Multiskan Flow Laboratories, North Ryde,
. yAustralia . NO was determined by using sodium2
nitrite as a standard. The cell-free medium alone
contained 5 to 8 mM of NOy; this value was deter-2
mined in each experiment and subtracted from the
value obtained from the medium with cells.
2.4. Preparation of probe
To detect of iNOS mRNA transcripts, sense and
antisense oligonucleotide primers specific for the
coding regions of that gene were synthesized by
using conventional technology. The following oligo-
nucleotide primers were used: Forward primer, 5X-
GGCCTTGGCTCCAGCATGTAC-3X, 1856 through
1876; and reverse primer, 5X-GCTGCCGCTCTCAT-
CCAGAAC-3X, 2395 through 2415. The numbers
represent the nucleotide numbers on the complemen-
w xtary strands of iNOS cDNA sequence 15 . Total
 .cellular RNA 5 mg from rIFNg-and LPS-stimulated
macrophages of C57BLr6 mice was used as a tem-
plate, and the single-stranded cDNA was synthesized
with downstream antisense primers by reverse tran-
scriptase. cDNA was amplified in a 12 ml reaction
mixture by using a DNA thermal cycler. For the
analysis of DNA sequence, PCR products were gel
purified, then treated with T4 polynucleotide kinase,
and with the Klenow fragment of DNA polymerase I.
The products were subcloned into the EcoRV site of
 .the pBluescript II KS y plasmid. 1 mg of plasmid
wDNA was radiolabeled by random priming with a-
32 xP dCTP. The resultant specific activity was approx-
imately 1=108 cpm mgy1 and was used at 1=107
cpm bloty1.
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Fig. 1. Effects of hCG on the induction of NO synthesis in RAW
 .  y1.264.7 cells. A Effects of hCG 0.1 mg ml on NO synthesis
 5.in rIFNg-treated cells. RAW 264.7 cells 2=10 were cultured
 y1.with rIFNg 5 U ml . The cells were then stimulated with hCG
 .at 6 h after incubation. Control CON . B: Dose-dependent effect
 y1.of hCG on NO synthesis in rIFNg 5 U ml -treated cells. After
48 h of culture, NO release was measured by the Griess method
 .nitrite . Values are the means"SEM of duplicate determinations
) .from three separate experiments P -0.01 .
2.5. RNA isolation and Northern blot analysis
Total RNA was isolated by using the modified
w xLiCl–urea method 16 , electrophoresis in 1.2%
agarose–formaldehyde gels, and transferred to nylon
membranes by capillary action in 20=SSC 1=
SSCs0.15 M NaCl and 0.015 M sodium citrate, pH
.7.2 . After prehybridization, the filters were hy-
w 32 xbridized with random a- P dCTP-labeled probes
having specific activity of 1 to 5=108 cpm mgy1 in
10% dextran sulfate, 50% formamide, 4=SSC, 1=
Denhardt’s solution, and 10 mg mly1 salmon sperm
DNA for 24 h at 428C. Then the filters were washed,
dried, and examined by autoradiography.
2.6. Assay of TNF-a secretion
TNF-a secretion was measured by modification of
w xan ELISA, as previously described 17 . The ELISA
was sensitive to TNF-a concentrations in medium
above 40 pg mly1. The ELISA was devised by
coating 96-well plates with 6.25 ng welly1 of murine
monoclonal antibody with specificity for human
TNF-a. Before use and between subsequent steps in
the assay, coated plates were washed twice with PBS
 .containing 0.05% Tween 20 PBS–Tween and twice
with PBS alone. All reagents used in this assay were
incubated for 1 h at room temperature with coated
wells. For the standard curve, rTNF-a was added to
serum previously determined to be negative for en-
dogenous TNF-a . After exposure to medium, assay
plates were sequentially exposed to rabbit anti-TNF-
a , phosphatase-conjugated goat anti-rabbit IgG, and
2,2X-azinobis. OD readings were made within 10 min
of addition of the substrate on a Titertek Multiskan
with a 405 nm filter. Appropriate specificity controls
were included.
3. Results
3.1. Effect of hCG on rIFNg-induced NO production
RAW 264.7 cells were cultured for 6 h either in
medium alone or in medium that contained rIFNg 5
y1.U ml . Thereafter, the cells were treated with hCG
 y1.0.1 mg ml , cultured for 42 h, and NO release was
 .measured by using the Griess method nitrite . As
Fig. 1A shows, hCG alone induced only a small
Fig. 2. Effects of NO synthase inhibitors on hCG 0.1 mg
y1.ml -induced nitrite accumulation in the cultured medium of
 5.RAW 264.7 cells. RAW 264.7 cells 2=10 were incubated
with rIFNg plus N GMMA. The cells were incubated for 6 h in
the presence of rIFNg plus N GMMA. The cells were then
treated with hCG and cultured for 42 h. NO release was mea-
 .sured by the Griess method nitrite . Values are means"SEM of
)duplicate determinations from three separate experiments P -
.0.01 .
( )E.-H. Lee, H.-M. KimrBiochimica et Biophysica Acta 1359 1997 59–6462
amount of NO synthesis, whereas hCG in combina-
tion with rIFNg synergistically increased NO synthe-
sis in RAW 264.7 cells. The dose-dependent effects
of hCG in the presence of rIFNg of NO synthesis
were shown in the Fig. 1B. The synergistic effect
always was maximal at 0.1 mg mly1 of hCG.
3.2. Inhibition of NO production by N GMMA, a
competiti˝e inhibitor of NO synthase
To determine if the signaling mechanism in hCG-
induced NO production is involved in the L-arginine-
dependent pathway in RAW 264.7 cells, the cells
were incubated for 6 h in the presence of rIFNg plus
N GMMA. The hCG-induced accumulation of nitrite
G was significantly blocked by N MMA 1 mM, 10
.  .mM Fig. 2 .
3.3. Effect of hCG on rIFNg-induced iNOS gene
expression
Data in Fig. 3 show the effects of hCG or rIFNg
plus hCG treatments on the expression of iNOS gene
 y1.Fig. 3. Effects of hCG 0.1 mg ml on the expression of the
 y1.iNOS gene in rIFNg 5 U ml -treated RAW 264.7 cells. The
cells were plated at 5=107 cellsr100-mm diameter petri dishes
and were cultured for 6 h either in medium containing rIFNg
 .  .lane 1 , or rIFNg plus hCG lane 2 . Each of the cells were
cultured for 18 h. Total cellular RNA was prepared and iNOS
mRNA was analyzed by Northern blotting. The amounts of
loaded RNA samples were monitored by the expression of b-actin.
Table 1
Effects of hCG on the secretion of TNF-a by rIFNg , hCG, or
rIFNg plus hCG-stimulated RAW 264.7 cells
y1 .Treatment TNF-a secretion ng ml
None 0.133"0.015
rIFNg 0.986"0.074
hCG 0.528"0.020
))rIFNg qhCG 5.142"0.644
 6 y1.RAW 264.7 cells 1=10 cells well were cultured with
medium alone, 5 U mly1 rIFNg , 0.1 mg mly1 hCG, or rIFNg
plus hCG. The amount of TNF-a secreted by RAW 264.7 cells
was measured after 24 h of incubation. Values are the means"
SEM of duplicate determinations from three separate experiments
)) .P -0.001 .
in RAW 264.7 cells. Total RNA was isolated from
cultured cells, separated by denaturing agarose gel
electrophoresis, and analyzed by Northern blotting
with radiolabeled cDNA that encoded iNOS gene.
Expressed iNOS mRNA levels were correlated with
the amounts of nitrite secreted into the medium.
rIFNg caused only modest, whereas rIFNg plus hCG
 .caused marked increases in iNOS mRNA Fig. 3 .
Fig. 4. Effects of anti-TNF-a neutralizing antibody on rIFNg or
rIFNg plus hCG-induced NO synthesis in RAW 264.7 cells.
 y1.RAW 264.7 cells were stimulated with rIFNg 5 U ml or
 y1.rIFNg plus hCG 0.1 mg ml , the cells were then treated with
 .anti-TNF-a antibody dilution, 1:50 . Anti-IL-1-neutralizing anti-
 .body dilution, 1:50 was used as a control. After 48 h of culture,
 .NO release was measured by the Griess method nitrite . Values
are the means"SEM of duplicate determinations from three
) .separate experiments P -0.01 .
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3.4. Effect of hCG on rIFNg-induced TNF-a secre-
tion
RAW 264.7 cells secreted very low levels of bio-
logically active TNF-a after 24 h incubation with
medium alone, 5 U mly1 of rIFNg alone, or 0.1 mg
y1  .ml of hCG alone Table 1 . However, RAW 264.7
cells secreted high levels of biologically active TNF-a
after incubation with rIFNg plus hCG. In addition, as
Fig. 4 shows, hCG-induced NO production was pro-
gressively inhibited by the use of anti-murine TNF-a
neutralizing antibody, indicating that hCG-induced
TNF-a secretion is crucial for synergistic induction
of NO synthesis in RAW 264.7 cells.
4. Discussion
The results of this study suggest that hCG may
provide a second signal for synergistic induction of
NO synthesis in RAW 264.7 cells already induced to
express iNOS mRNA by rIFNg. This hypothesis is
confirmed by the fact that RAW 264.7 cells cultured
with hCG for 6 h presented high levels of a 4.4 kb
mRNA which hybridized with a cDNA for iNOS.
NO, the initial product of oxidation of L-arginine,
w xexhibits a multitude of biological actions 18,19 . The
strong inhibition of NOy production by N GMMA2
indicates that it is likely to depend upon a NO
synthase.
Within the past decade, hCG receptor has been
identified in nongonadal reproductive tissues, such as
the uterine tubes, umbilical cord, uterus, brain of
many species, and vascular smooth muscle and en-
w xdothelial cells of uterine blood vessels 20–22 . At
present, the physiological significance of NO synthe-
sis by hCG is unknown. However, since NO has
emerged as an important intracellular and intercellu-
lar regulatory molecule having functions as diverse as
vasodilation, neural communication, cell growth reg-
w xulation and host defense 23 , it is tempting to hy-
pothesize that this molecule is involved in the local
control of the various fundamental processes. In vivo
administration of inhibitors of NO synthase to go-
nadotropin-treated rats inhibits ovulation, whereas
concomitant treatment with a NO generator enhances
w xovulation 24 . We determined that hCG can induce
biologically active TNF-a secretion in RAW 264.7
cells. These results indicate the potential for hCG to
induce host defense mechanisms.
In conclusion, our results demonstrate that hCG
acts as a modulator of RAW 264.7 cells activation by
rIFNg via process involving L-arginine dependent
NO production. hCG dose not appear to function as
an activator of NO synthesis by itself. Although the
precise mechanism of hCG to promote NO synthesis
induced by rIFNg remains to be further elucidated,
NO production by activation of intracellular signals
might be important in the development of macrophage
activation.
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